

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Ocumention Therapeutics**  
**歐康維視生物**

*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock Code: 1477)**

## **RETIREMENT AND PROPOSED APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR**

### **RETIREMENT OF AN INDEPENDENT DIRECTOR**

The board (the “**Board**”) of directors (the “**Directors**”) of Ocumention Therapeutics (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that, Mr. Ting Yuk Anthony WU (胡定旭) (“**Mr. Wu**”), after more than five years of service, shall retire from office at the forthcoming annual general meeting of the Company (“**AGM**”) in accordance with the articles of association of the Company (“**Articles and Associations**”). Mr. Wu has informed the Board that he has decided not to offer himself for re-election at the AGM in order to devote more time on his other commitments. With effect from the conclusion of the AGM, Mr. Wu will retire as an independent non-executive Director, and will cease to be the chairman of the audit committee of the Board (the “**Audit Committee**”) and a member of each of the remuneration committee (the “**Remuneration Committee**”) and nomination committee (“**Nomination Committee**”) of the Board.

Mr. Wu has confirmed that he has no disagreement with the Board and there is no matter in connection with his retirement as an independent non-executive Director that should be brought to the attention of the shareholders of the Company (the “**Shareholders**”). The retirement of Mr. Wu will not affect the operation of the Board and the Company. The Board would like to express its sincere gratitude to Mr. Wu for his invaluable contribution to the Company during his tenure of office.

### **PROPOSED APPOINTMENT OF A NON-EXECUTIVE DIRECTOR**

In view of Mr. Wu’s pending retirement, on March 26, 2026, the Board resolves to propose the appointment of Ms. Beibei ZHUANG (莊蓓蓓) (“**Ms. Zhuang**”) as an independent non-executive Director at the AGM to fill the vacancy on the Board following the retirement of Mr. Wu with effect from the conclusion of the AGM, subject to approval by the Shareholders. The Board further resolves to appoint Ms. Zhuang as the chairwoman of the Audit Committee and a member of each of the Remuneration Committee and the Nomination Committee, with effect from her appointment as an independent non-executive Director being approved by the Shareholders at the AGM.

The biographical details of Ms. Zhuang are as follows:

**Ms. Zhuang**, aged 45, has over 15 years of experience in auditing and financial services. From August 2006 to May 2025, she worked at PricewaterhouseCoopers Zhong Tian LLP (普華永道中天會計師事務所(特殊普通合夥)) where her last position was an audit partner. In June 2025, she joined BDO China Shu Lun Pan Certified Public Accountants LLP (立信會計師事務所(特殊普通合夥)) as an audit partner. Ms. Zhuang possesses in-depth professional knowledge and extensive practical experience in the field of auditing, with a thorough and comprehensive understanding of Chinese Accounting Standards for Business Enterprises, International Financial Reporting Standards, and relevant regulatory requirements. She has led audit engagements for numerous companies and is well-positioned to contribute to the Group's financial reporting, internal controls and compliance matters.

Ms. Zhuang graduated from Nanjing Audit University (南京審計大學) in June 2003 with a bachelor's degree in financial management. She also obtained the Certified Internal Auditor (CIA) qualification in November 2005, the China Certified Public Accountant (CPA) qualification certificate in June 2008, and the CPA practicing certificate in May 2010.

The Board considered and accepted the recommendation from the Nomination Committee to appoint Ms. Zhuang as an independent non-executive Director, after reviewing her academic qualification and work experience, among others. The Nomination Committee and the Board also assessed and reviewed the independence of Ms. Zhuang pursuant to the independence guidelines set out in Rule 3.13 of the the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**"), and considered that Ms. Zhuang is independent and an appropriate candidate to fill the casual vacancy arising from the retirement of Mr. Wu.

Subject to the approval of the Shareholders, Ms. Zhuang will enter into a letter of appointment with the Company for a term of three years commencing from the date of the AGM and will be subject to retirement by rotation and re-election at least once every three years in accordance with the Articles of Association. Ms. Zhuang will be entitled to a director's fee of HK\$200,000 per annum under the letter of appointment, which was recommended by the Remuneration Committee and determined by the Board with reference to Ms. Zhuang's academic and professional qualifications and experience, as well as her duties and level of responsibilities within the Group for the relevant position. Ms. Zhuang may also receive additional benefits as the Board or its authorized person(s) shall in its absolute discretion deems appropriate for her term of appointment as an independent non-executive Director.

As of the date of this announcement, Ms. Zhuang does not have any interests in any Shares within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). Save as disclosed above, during the three years immediately before her proposed appointment, Ms. Zhuang had not held any directorship in other listed public companies in Hong Kong or overseas. Ms. Zhuang is not related to any Directors, senior management or substantial or controlling shareholders of the Company and did not hold other positions with other members of the Group. Ms. Zhuang has not been subject to any penalty or punishment imposed by any relevant authorities or stock exchanges.

Ms. Zhuang has confirmed that (i) she has satisfied all the factors for independence as set out in Rule 3.13(1) to (8) of the Listing Rules; (ii) she has no past or present financial or other interest in the business of the Group or connection with any core connected person (as defined in the Listing Rules) of the Company; and (iii) there are no other factors that may affect her independence at the time of her proposed appointment. Ms. Zhuang has obtained the legal advice referred to under Rule 3.09D of the Listing Rules prior to her proposed appointment.

Save as disclosed above, the Board is not aware of any other matters that need to be brought to the attention of the Shareholders in connection with Ms. Zhuang's proposed appointment as an independent non-executive Director, or any other information that needs to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules.

A circular containing, among other things, details of the proposed appointment of Ms. Zhuang, together with a notice of the AGM, will be dispatched to the Shareholders in due course.

By order of the Board  
**Ocumension Therapeutics**  
**Dr. Lian Yong CHEN**  
*Chairman and Non-executive Director*

Hong Kong, March 26, 2026

*As of the date of this announcement, the Board comprises Mr. Ye LIU and Dr. Zhaopeng HU as executive Directors, Dr. Lian Yong CHEN, Mr. Yanling CAO and Dr. Qin XIE as non-executive Directors, and Mr. Wu, Mr. Yiran HUANG and Mr. Zhenyu ZHANG as independent non-executive Directors.*